Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 15/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12796332 | 0.90 | AVPR1A (0.46) | AVPR1ASCN9AOXTROPRD1SPR | |
| SCHEMBL10145229 | 0.86 | AVPR1A (0.47) | AVPR1ASCN9AOPRD1 | |
| SCHEMBL12795989 | 0.82 | KDM4E (0.54) | AVPR1ASCN9A | |
| SCHEMBL541322 | 0.75 | OPRL1 (0.41) | SCN9AOPRL1 | |
| SCHEMBL12796494 | 0.71 | CNR2 (0.51) | — | |
| SCHEMBL15963529 | 0.70 | AVPR1A (0.64) | AVPR1AOXTRSPR | |
| SCHEMBL15963090 | 0.69 | AVPR1A (0.51) | AVPR1AOXTR | |
| SCHEMBL541568 | 0.69 | SCD (0.48) | SPR | |
| SCHEMBL10146161 | 0.68 | P2RY1 (0.37) | OPRL1 | |
| SCHEMBL12796252 | 0.68 | PTPN11 (0.48) | SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | AVPR1A 1069/4885SCN9A 1900/4885OXTR 479/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | AVPR1A 930/4885SCN9A 1917/4885OXTR 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.